| 73.9 -3.25 (-4.21%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 94.08 |
1-year : | 99.94 |
| Resists | First : | 80.55 |
Second : | 85.56 |
| Pivot price | 77.56 |
|||
| Supports | First : | 72.43 |
Second : | 60.26 |
| MAs | MA(5) : | 75.69 |
MA(20) : | 78.39 |
| MA(100) : | 83.96 |
MA(250) : | 77  |
|
| MACD | MACD : | -1.7 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 22.1 |
D(3) : | 23.2 |
| RSI | RSI(14): 34.6 |
|||
| 52-week | High : | 99.5 | Low : | 56.7 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ANIP ] has closed below the lower bollinger band by 2.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ANIP ] is to continue within current trading range. Bollinger Bands are 6.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 77.53 - 78.08 | 78.08 - 78.5 |
| Low: | 74.61 - 75.19 | 75.19 - 75.64 |
| Close: | 76.39 - 77.29 | 77.29 - 77.99 |
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Sat, 28 Feb 2026
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2025 Earnings Call Transcript - Insider Monkey
Sat, 28 Feb 2026
ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4% - The Globe and Mail
Sat, 28 Feb 2026
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
Fri, 27 Feb 2026
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50% - Benzinga
Fri, 27 Feb 2026
ANI Pharmaceuticals (ANIP) Surpasses Q4 Earnings and Revenue Estimates - Nasdaq
Fri, 27 Feb 2026
ANI Pharmaceuticals Reaffirms FY26 Outlook; Swings To Profit In Q4; Stock Up 7.6% - Update - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 22 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 100.5 (%) |
| Shares Short | 3,470 (K) |
| Shares Short P.Month | 2,960 (K) |
| EPS | 1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 24.19 |
| Profit Margin | 4.9 % |
| Operating Margin | 10.1 % |
| Return on Assets (ttm) | 2.3 % |
| Return on Equity (ttm) | 8.6 % |
| Qtrly Rev. Growth | 53.5 % |
| Gross Profit (p.s.) | 22.36 |
| Sales Per Share | 36.81 |
| EBITDA (p.s.) | 6.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 171 (M) |
| Levered Free Cash Flow | 116 (M) |
| PE Ratio | 45.76 |
| PEG Ratio | 0 |
| Price to Book value | 3.02 |
| Price to Sales | 1.98 |
| Price to Cash Flow | 9.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|